5-Day Storage of Human Platelet Concentrates in 30 ml of
Plasma or Artificial Medium

Adams, George A.; Swenson, Sonia D.; Rock, G.

doi:10.1159/000461670

Cited by 4 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other artificial media are under devel opment by several investigators [17][18][19][20] in a similar effort to provide an alternative to the storage of platelets in plasma. One of the direct benefits of the storage in a nonplasma medium may be derived from the removal of plasma com ponents which could lead to the generation of potent plate let agonists such as thrombin, plasmin, or C3a [1,13,14].…”

Section: Discussionmentioning

confidence: 99%

Extended Storage of Platelets in an Artificial Medium with the Platelet Activation Inhibitors Prostaglandin E(1) and Theophylline

Bode¹,

Holme²,

Heaton³

et al. 1991

Vox Sanguinis

View full text Add to dashboard Cite

The addition of platelet activation inhibitors to the anticoagulant and the replacement of plasma with a fortified electrolyte medium have been shown separately in previous work to improve the storage of platelets during a 2-week period. In the present study, we have combined these strategies to investigate whether a synergistic improvement could be obtained. A total of 85 concentrates was studied with 300nM prostaglandin E(1) (PGE(1)) and 1.9mM theophylline added to the whole blood, platelet-rich plasma (PRP), and/or the storage medium during the preparation of platelet concentrates. In vitro markers of platelet aggregation, respiration, and cell integrity were measured over a 20-day storage period and evaluated in an analysis of variance. We found that a single-step addition of PGE(1) and theophylline to the PRP prior to centrifugation was not sufficient in terms of preventing a rapid fall in pH, rise in pO(2), fall in pCO(2), loss of hypotonic shock response, and loss of aggregation response, compared to the addition of the inhibitors to the storage medium used to resuspend the platelet pellet. Factorial analysis showed that a reduction in the surface-to-volume ratio of the storage container further improved the maintenance of platelet respiration and, for three in vitro markers (hypotonic shock response, released lactic dehydrogenase, and surface glycoprotein lb levels) displayed an interactive effect with the inhibitors. The addition of protease inhibitors to the formulation of PGE(1) and theophylline showed further improvement in several markers. These findings demonstrate the possibility of preserving platelets for 15-20 days with the synergistic effects of activation inhibitors and an electrolyte storage medium fortified with citrate, buffers, and dextrose. In addition, these data suggest that platelet agonists generated in plasma accelerate the in vitro aging process of stored platelets.

show abstract

Section: Discussionmentioning

confidence: 99%

Extended Storage of Platelets in an Artificial Medium with the Platelet Activation Inhibitors Prostaglandin E(1) and Theophylline

Bode¹,

Holme²,

Heaton³

et al. 1991

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…The results this study confirms that lower volumes result in undesirable lower pH than higher final volumes. In another study Fasola (13) reported the mean volume was considerably low 18.52ml compared to (12) reported a mean of 62.30±22.68 ml. This study also demonstrates that Haemoglobin (Hb) and platelet counts can form an integral part of a rapid, simple and practical method for validation of collection, processing and storage procedures that is useful for routine quality monitoring and pre-release testing of platelet concentrates.…”

Section: Discussionmentioning

confidence: 80%

“…After the second spin 3800 rpm for 9 minutes yielding the platelet concentrate, 83/87 (95.4%) had the required platelet count, (≥450 cells/ml) mean±SD was 783.813±232.24 and concentrate volume (40-70 ml). In a study by Fasola (13) , the mean volume was considerably low (18.52mls) whereas Singh reported a mean of 62.30±22.68 ml. NBTS set minimum volume at 60ml whereas AABB do not have a specified minimum volume.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Quality Assessment of Platelet Concentrate Preparations at the Nairobi Regional Blood Transfusion Centre in Kenya

Margare¹,

Mbugua²,

Mwamba³

et al. 2017

IAM

View full text Add to dashboard Cite

Background: Evaluation of platelet concentrate was based on platelet volume, count, residual WBC and Hemoglobin. The study findings were compared with standards set by National Blood Transfusion Service (NRBTC). Objective: To evaluate platelet concentrates quality prepared at NRBTC. Study Design:This was a descriptive cross-sectional study was adopted. Setting: The present study was conducted at NRBTC. Subject: Nighty one (91) platelet concentrates were selected for the study. Results: Of the samples analyzed, 95.6% (87/91), 79.1% (72/91) met the criteria on platelet count and residual white blood cells respectively.Of note, all the 91 sampled platelet concentrate fell within the NRBTS volume criteria. Conclusion: The findings reveals that the quality parameters assessed in this study from the platelet concentrate were not met. Therefore, there is need to review the quality assurance protocol.Focus should be directed on the platelet concentrates preparation by plasma centrifugation to attain the desirable standards set by NBTS.

show abstract

“…Certainly, red cell storage studies showed the di(2-ethylhexyl) phthalate plasticizer helps maintain red cell viability during storage. 27,28 In vitro platelet assays suggest that the storage bag [29][30][31][32] and even the method of bag sterilization 33 may affect platelet quality during storage. When Terumo BCT platelets were stored in Haemonetics CLX bags, there were clear improvements in poststorage platelet viability, but the results may still not be as good as Haemonetics platelets stored in Haemonetics CLX bags (Table 3).…”

Section: Discussionmentioning

confidence: 99%

Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS)

Slichter

Corson

Jones

et al. 2014

Blood

View full text Add to dashboard Cite

• Extended apheresis platelet storage is dependent on the collection method, storage in a storage solution, and storage bag composition.• The lifespan of the platelet is not intrinsic to the cell, and platelet viability is better maintained in vitro than in vivo.To evaluate the poststorage viability of apheresis platelets stored for up to 18 days in 80% platelet additive solution (PAS)/20% plasma, 117 healthy subjects donated platelets using the Haemonetics MCS1, COBE Spectra (Spectra), or Trima Accel (Trima) systems. Control platelets from the same subjects were compared with their stored test PAS platelets by radiolabeling their stored and control platelets with either 51 chromium or 111 indium. Trima platelets met Food and Drug Administration poststorage platelet viability criteria for only 7 days vs almost 13 days for Haemonetics platelets; ie, platelet recoveries after these storage times averaged 44 6 3% vs 49 6 3% and survivals were 5.4 6 0.3 vs 4.6 6 0.3 days, respectively. The differences in storage duration are likely related to both the collection system and the storage bag. The Spectra and Trima platelets were hyperconcentrated during collection, and PAS was added, whereas the Haemonetics platelets were elutriated with PAS, which may have resulted in less collection injury. When Spectra and Trima platelets were stored in Haemonetics' bags, poststorage viability was significantly improved. Platelet viability is better maintained in vitro than in vivo, allowing substantial increases in platelet storage times. However, implementation will require resolution of potential bacterial overgrowth during storage. (Blood. 2014;123(2):271-280)

show abstract

5-Day Storage of Human Platelet Concentrates in 30 ml of Plasma or Artificial Medium

Cited by 4 publications

References 7 publications

Extended Storage of Platelets in an Artificial Medium with the Platelet Activation Inhibitors Prostaglandin E(1) and Theophylline

Extended Storage of Platelets in an Artificial Medium with the Platelet Activation Inhibitors Prostaglandin E(1) and Theophylline

Quality Assessment of Platelet Concentrate Preparations at the Nairobi Regional Blood Transfusion Centre in Kenya

Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS)

Contact Info

Product

Resources

About